Hence, anti-CLEC12A CAR T cells can potentially be used as a consolidation regimen after induction chemotherapy to eradicate LSC and minimal residual disease (MRD) in AML [81]. This evidence concerns the gene CLEC12A and acute myeloid leukemia.